Phase II Clinical Trial of Eribulin in Advanced or Recurrent Cervical Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2019
At a glance
- Drugs Eribulin (Primary)
- Indications Cervical cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Jun 2019 Planned End Date changed from 9 Aug 2020 to 9 Aug 2021.
- 17 Jun 2019 Planned primary completion date changed from 9 Aug 2019 to 9 Aug 2020.
- 31 Aug 2018 Biomarkers information updated